These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2414366)

  • 1. The immune response to a schistosomacide, amoscanate. I. Serum antibody responses.
    Barton BE; Levy DA
    J Immunopharmacol; 1985; 7(3):343-71. PubMed ID: 2414366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immune response to a schistosomacide, amoscanate. II. Cell-mediated immune responses.
    Barton BE; Levy DA
    J Immunopharmacol; 1985; 7(3):373-83. PubMed ID: 4056413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of amoscanate against experimental schistosomal infections in monkeys.
    Crawford KA; Asch HL; Bruce JI; Bueding E; Smith ER
    Am J Trop Med Hyg; 1983 Sep; 32(5):1055-64. PubMed ID: 6625061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of the mutagenic activation of an antischistosomal isothiocyanate in primates by an antibiotic.
    Batzinger RP; Bueding E; Crawford K; Bruce J
    Environ Mutagen; 1979; 1(4):353-60. PubMed ID: 553807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutagenic activation of an antischistosomal drug by enteric Streptococcus sps in vitro and in vivo.
    Molineaux CJ; Batzinger RP; Schmidt W; Bueding E
    Teratog Carcinog Mutagen; 1980; 1(2):129-39. PubMed ID: 6119805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of amoscanate derivatives in experimental schistosomiasis].
    Yue WJ; Shao BR; Pan QR; You JQ; Mei JY
    Yao Xue Xue Bao; 1983 Jul; 18(7):541-4. PubMed ID: 6659959
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion of amoscanate to a mutagenic metabolite in gnotobiotic mice implanted with Streptococcus equinus.
    Reddy BS; Batzinger RP; Molineaux CJ; Bueding E
    Antimicrob Agents Chemother; 1982 Oct; 22(4):707-8. PubMed ID: 7181482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection by antibiotics against experimental focal cholangitis produced in mice by a schistosomicidal isothiocyanate.
    Batzinger RP; Bueding E; Popper H
    Hepatology; 1981; 1(1):21-7. PubMed ID: 7286888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoscanate as a topically applied chemical for prophylaxis against Schistosoma mansoni infections in mice.
    Greene LK; Grenan MM; Davidson DE; Jones DH; Shedd TR
    Am J Trop Med Hyg; 1983 Nov; 32(6):1356-63. PubMed ID: 6650736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioimmunoassay for an antischistosomal drug, 4-nitro-4'-isothiocyano-diphenylamine (7505) (author's transl)].
    Wang ZT; Wang DN; Li Q; Ouyang HJ
    Yao Xue Xue Bao; 1980 Aug; 15(8):463-9. PubMed ID: 7211390
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical observation on schistosomiasis japonica treated with amoscanate and phenithionate in a hyperendemic area].
    Zhou GX
    Zhonghua Nei Ke Za Zhi; 1983 Oct; 22(10):634-5. PubMed ID: 6673935
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuropathology of the antischistosomal agent amoscanate administered in high oral doses to rats.
    Clark AW; Kiel SM; Parhad IM
    Neurotoxicology; 1982 Nov; 3(3):1-11. PubMed ID: 6891757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the effect of Amoscanate on the immature stages of S. mansoni and S. haematobium worms in hamsters.
    Khalil SB; Girgis NI; Mansour NS
    J Egypt Soc Parasitol; 1986 Dec; 16(2):699-706. PubMed ID: 3097173
    [No Abstract]   [Full Text] [Related]  

  • 14. [Amoscanate induced liver injury. I. Clinical observation (author's transl)].
    Miao HZ
    Zhonghua Nei Ke Za Zhi; 1981 Jul; 20(7):430-2. PubMed ID: 7327065
    [No Abstract]   [Full Text] [Related]  

  • 15. Schistosoma mansoni: tegumental surface alterations induced by subcurative doses of the schistosomicide amoscanate.
    Voge M; Bueding E
    Exp Parasitol; 1980 Oct; 50(2):251-9. PubMed ID: 7409075
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical evaluation of amoscanate in healthy male volunteers.
    Shapiro TA; Were JB; Talalay P; Bueding E; Rocco L; Danso K; Massof R; Green R; Mellits ED; Lietman PS
    Am J Trop Med Hyg; 1986 Sep; 35(5):945-53. PubMed ID: 3766854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schistosoma haematobium: amoscanate and adult worm ultrastructure.
    Leitch B; Probert AJ
    Exp Parasitol; 1984 Dec; 58(3):278-89. PubMed ID: 6500001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effects of high-dosed absorbable amoscanate on rat brain.
    Krinke G; Graepel P; Krueger L; Thomann P
    Toxicol Lett; 1983 Dec; 19(3):261-6. PubMed ID: 6658839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of 21 cases of jaundice caused by nithiocyaminum (amoscanate, C9333 GO/CGP4540) (author's transl)].
    Zhonghua Nei Ke Za Zhi; 1980 Mar; 19(2):132-4. PubMed ID: 7472043
    [No Abstract]   [Full Text] [Related]  

  • 20. Detectability and measurability of amoscanate in plasma by TLC and HPLC.
    Kofi-Tsekpo WM; Karekezi CW
    Drugs Exp Clin Res; 1988; 14(1):31-7. PubMed ID: 3391104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.